Article
Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment.
Cancer letters - 1 Jun 2018
Li Weihua, Qiu Tian, Guo Lei, Ling Yun, Gao Yibo, Ying Jianming, He Jie
Abstract excerpt
Primary EGFR T790M mutation is occasionally identified by routine mutation testing in tyrosine kinase inhibitor (TKI)-naive patients with non-small cell lung cancer (NSCLC). We herein aimed to compare the characteristics of primary and acquired T790M mutations in NSCLC patients, and their response to osimertinib. Using amplification refractory mutation system (ARMS) detection, primary T790M was identified in 0.5%...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.